Abstract 2094P
Background
Dexamethasone is one of the key antiemetic agents and is widely used even now. However, dexamethasone has been associated with a number of adverse reactions even after short-term administration. Therefore, the development of steroid-free antiemetic regimen is an important issue to be considered. Thus, the purpose of this study was to investigate the efficacy and safety of palonosetron, aprepitant, and olanzapine in a multi-institutional phase II study.
Methods
Chemotherapy-naive patients scheduled to receive for highly emetogenic chemotherapy in breast cancer were enrolled and evaluated the occurrence of chemotherapy-induced nausea and vomiting during 120 hours after chemotherapy. The primary endpoint of the study was total control (TC) in the overall phase. Key secondary endpoint was complete response (CR), which was assessed in the acute, delayed, and overall phase, respectively. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events.
Results
Eighty-nine patients were enrolled from 8 centers in Japan, of which 76 were evaluable for analyses. The percentage of patients achieved TC during the overall phase was 17.1% (95% confidence interval [CI] 0.094–0.275; p = 0.275). CR was achieved in 43.4% (95% CI 0.321–0.553; p = 0.726), 53.9% (95% CI 0.421–0.655), and 63.2% (95% CI 0.513–0.739) of patients during the overall, acute, and delayed phases, respectively
Conclusions
The primary endpoint was below the threshold and we could not find any benefit in the dexamethasone-free regimen. The CR rate was also examined as one of the secondary endpoints, with similar results. Although dexamethasone is considered to have side effect concerns, its effect on CINV cannot be ignored, suggesting that easy complete omission should be avoided.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Tsuji: Financial Interests, Personal, Invited Speaker: Taiho Phamaceutical Co., Ltd., Kyowa Kirin Co., Ltd. K. koizumi: Financial Interests, Personal, Invited Speaker: Pfizer, Chugai Pharmaceutical. K. Suzuki: Financial Interests, Personal and Institutional, Invited Speaker: Taiho, Nipro. All other authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06